Brokerages Anticipate Evoke Pharma Inc (EVOK) Will Post Earnings of -$0.22 Per Share
Brokerages predict that Evoke Pharma Inc (NASDAQ:EVOK) will report ($0.22) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have provided estimates for Evoke Pharma’s earnings, with estimates ranging from ($0.26) to ($0.18). Evoke Pharma reported earnings of ($0.18) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 22.2%. The business is expected to report its next quarterly earnings report after the market closes on Wednesday, March 7th.
According to Zacks, analysts expect that Evoke Pharma will report full year earnings of ($1.00) per share for the current fiscal year, with EPS estimates ranging from ($1.03) to ($0.96). For the next fiscal year, analysts anticipate that the business will post earnings of $0.09 per share, with EPS estimates ranging from ($0.54) to $1.16. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that cover Evoke Pharma.
Several brokerages have commented on EVOK. Zacks Investment Research upgraded shares of Evoke Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, January 31st. HC Wainwright set a $9.00 target price on shares of Evoke Pharma and gave the stock a “buy” rating in a report on Wednesday, November 29th. B. Riley restated a “buy” rating and set a $10.00 target price on shares of Evoke Pharma in a report on Wednesday, November 15th. Finally, ValuEngine downgraded shares of Evoke Pharma from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. Evoke Pharma currently has a consensus rating of “Buy” and an average price target of $9.14.
Shares of Evoke Pharma (EVOK) opened at $1.90 on Friday. The company has a market cap of $29.13, a P/E ratio of -2.02 and a beta of 1.49. Evoke Pharma has a fifty-two week low of $1.85 and a fifty-two week high of $4.09.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/brokerages-anticipate-evoke-pharma-inc-evok-will-post-earnings-of-0-22-per-share/1904960.html.
Evoke Pharma Company Profile
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.